02/02/23 9:00 AMNasdaq : AZN TEZSPIRE® approved for self-administration in the US with a new pre-filled penAstraZeneca and Amgen’ s TEZSPIRE ® has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America, said:“ Severe asthma continues to be a very complex condition to manage, so we welcome the TEZSPIRE...RHEA-AIneutral
01/30/23 8:00 AMNasdaq, OTC : AZN, DSNKY clinical trialTROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung CancerDaiichi Sankyo today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan in combination with pembrolizumab with or without platinum chemotherapy, in patients with previously untreated advanced or metastatic non-squamous non-small cell lung...RHEA-AIneutral
01/26/23 2:00 AMNasdaq, OTC : AZN, DSNKY ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo and AstraZeneca’ s ENHERTU ® has been approved in the European Union as monotherapy indicated for...RHEA-AIpositive
01/23/23 7:00 AMNasdaq : AZN acquisitionAstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc., for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had...RHEA-AIneutral
01/11/23 9:00 AMNasdaq : AZN AIRSUPRA™ (PT027) approved in the US for asthmaIt is being developed by AstraZeneca and Avillion. Bradley E. Chipps, Past President of the American College of Allergy, Asthma& Immunology and Medical Director of Capital Allergy& Respiratory Disease Center in Sacramento, US, said:“ People with asthma are at risk of severe exacerbations regardless of their disease severity or level of control.RHEA-AInegative
01/05/23 9:30 AMNasdaq : AZN Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung CancerTempus, a leader in artificial intelligence and precision medicine, today announced a prospective study, in collaboration with AstraZeneca, that aims to identify biomarkers of response in patients with small cell lung cancer. The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’ s Personalize SCLC Initiative and is currently open for...RHEA-AIneutral
01/05/23 1:00 AMNasdaq : AZN Genomic Vision Announces Successful Beta Testing of FiberSmart®FiberSmart ® is Genomic Vision’ s Artificial Intelligence powered and fully integrated software automating genomic analysis FiberSmart ® leverages cutting-edge AI to rapidly analyze DNA replication kinetics and provide a seamless user experience FiberSmart platform was successfully tested by AstraZeneca and the Fritz Lipmann Institute.RHEA-AIpositive
01/04/23 2:00 AMNasdaq, OTC : AZN, DSNKY ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo today announced that the European Medicines Agency has validated the Type II Variation application for ENHERTU ® as a monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations and who have received a prior systemic therapy.RHEA-AIneutral
12/19/22 2:00 AMNasdaq, OTC : AZN, DSNKY ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric CancerDaiichi Sankyo and AstraZeneca’ s ENHERTU ® has been approved in the European Union as a monotherapy for...RHEA-AIpositive
12/19/22 2:00 AMNasdaq, OTC : AZN, DSNKY ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo and AstraZeneca’ s ENHERTU ® has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable...RHEA-AIpositive
